Back
IVL-GeneFluidic®
Technology Introduction
IVL-GeneFluidic® is an LNP (Lipid Nanoparticle)–based delivery platform designed for the development of mRNA vaccines and gene therapeutics. Utilizing continuous microfluidic mixing technology, it enables the production of highly reproducible, high-quality nanoparticles from lab scale to GMP scale. Through precise control of lipid composition and uniform particle formation, it allows optimized formulation design for various genetic materials. It provides core infrastructure for mRNA vaccines and gene therapeutics through large-scale GMP continuous processing.
Business Model
1. HANDYGENE™ Equipment based Commercialization
We have developed three types of HANDYGENE equipment (Lab, GMP, Commercial) optimized for Lab-to-GMP implementation. Currently, these are used for LNP CDMO business, and we provide sales options for customers needing our LNP manufacturing system.
2. CDMO
For the CDMO service business based on the IVL-GeneFluidic® platform, we have signed a joint LNP CDMO commercialization contract with EuBiologics Co., Ltd. for GMP-level production. Additionally, we plan to install HANDYGENE™ systems at the Curatis Osong Bio Plant to expand LNP manufacturing and CDMO services in a GMP environment.
